[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352640-105":59,"doc-detail-352640-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","gastric-neoplasm-risk-with-dpp-4-inhibitors-glp-1-receptor-agonists-and-sglt2-inhibitors-network-meta-analysis-of-randomized-trials","Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors - Network Meta-Analysis of Randomized Trials","","Whether newer glucose-lowering therapies alter the risk of incident gastric neoplasms remains uncertain. Decision-grade comparative safety evidence is needed because DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors have widespread global uptake and prolonged use in populations predisposed to malignancy. A systematic review and network meta-analysis of randomized controlled trials in adults without baseline gastric neoplasms estimated relative risks using frequentist random-effects and Bayesian sensitivity analyses, with evidence certainty assessed by GRADE adapted for network meta-analysis.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gastric-neoplasm-risk-with-dpp-4-inhibitors-glp-1-receptor-agonists-and-sglt2-inhibitors-network-meta-analysis-of-randomized-trials/352640/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gastric-neoplasm-risk-with-dpp-4-inhibitors-glp-1-receptor-agonists-and-sglt2-inhibitors-network-meta-analysis-of-randomized-trials/352640.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What clinical uncertainty does the study address?","Question",{"text":113,"@type":114},"It evaluates whether newer glucose-lowering therapies—DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors—modify the risk of incident gastric neoplasms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What study design and evidence base were used?",{"text":118,"@type":114},"The work is a systematic review and network meta-analysis of randomized controlled trials in adults without baseline gastric neoplasms.",{"name":120,"@type":111,"acceptedAnswer":121},"How were comparative risks estimated and checked?",{"text":122,"@type":114},"Frequentist random-effects network meta-analysis produced risk ratios with 95% confidence intervals, and Bayesian network meta-analysis was used as a sensitivity analysis.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352640,1790154153,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":81,"preview_urls":147},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","Article  \nGastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors: Network Meta-Analysis of Randomized Trials  \nChao-Ming Hung 1,2,†, Chih-Wei Hsu 3,†, Bing-Syuan Zeng 4, Mein-Woei Suen 5,6,7,8, Jiann-Jy Chen 9,10, Bing-Yan Zeng 11,12, Andre F. Carvalho 13, Brendon Stubbs 14,15,16, Yen-Wen Chen 9, Tien-Yu Chen 17,18, Shih-Pin Hsu 2,19, Hung-Yu Wang 20, Chih-Sung Liang 21,22, Yu-Kang Tu 23,24, * and Ping-Tao Tseng 9,25,26, *  \nAcademic Editors: Hidekazu Suzuki and Stergios Boussios  \nReceived: 15 January 2026  \nRevised: 10 February 2026  \nAccepted: 10 March 2026  \nPublished: 13 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Division of General Surgery, Department of Surgery, E-Da Cancer Hospital, I-Shou University, Kaohsiung 824, Taiwan; [ed100647@edah.org.tw](ed100647@edah.org.tw)  \n2 School of Medicine, College of Medicine, I-Shou University, Kaohsiung 824, Taiwan; [a.pin.hsu@gmail.com](a.pin.hsu@gmail.com)  \n3 Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan; [harwicacademia@gmail.com](harwicacademia@gmail.com)  \n4 Department of Internal Medicine, E-Da Cancer Hospital, I-Shou University, Kaohsiung 824, Taiwan; [b95401072@ntu.edu.tw](b95401072@ntu.edu.tw)  \n5 Department of Psychology, College of Medical and Health Science, Asia University, Taichung 413, Taiwan; [blake@asia.edu.tw](blake@asia.edu.tw)  \n6 Gender Equality Education and Research Center, Asia University, Taichung 413, Taiwan  \n7 Department of Medical Research, Asia University Hospital, Asia University, Taichung 413, Taiwan  \n8 Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 406, Taiwan  \n9 Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung 811, Taiwan; [jiannjy@yahoo.com.tw](jiannjy@yahoo.com.tw) (J.-J.C.); [kevinachen0527@gmail.com](kevinachen0527@gmail.com) (Y.-W.C.)  \n10 Department of Otorhinolaryngology, E-Da Cancer Hospital, I-Shou University, Kaohsiung 824, Taiwan  \n11 Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung 804, Taiwan; [holdinggreat@yahoo.com.tw](holdinggreat@yahoo.com.tw)  \n12 Department of Internal Medicine, E-Da Dachang Hospital, I-Shou University, Kaohsiung 807, Taiwan  \n13 Innovation in Mental and Physical Health and Clinical Treatment (IMPACT) Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, VIC 3216, Australia; [canaldasaudemental@gmail.com](canaldasaudemental@gmail.com)  \n14 Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London WC2R 2LS, UK; [brendon.stubbs@kcl.ac.uk](brendon.stubbs@kcl.ac.uk)  \n15 Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, 1090 Vienna, Austria  \n16 Clinical Division of Social Psychiatry, Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090 Vienna, Austria  \n17 Department of Psychiatry, Tri-Service General Hospital, Taipei 114, Taiwan; [verducciwol@gmail.com](verducciwol@gmail.com)  \n18 Department of Psychiatry, College of Medicine, National Defense Medical University, Taipei 114, Taiwan  \n19 Department of Neurology, E-Da Hospital, I-Shou University, Kaohsiung 824, Taiwan  \n20 Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung 802, Taiwan; [hywang1975@gmail.com](hywang1975@gmail.com)  \n[21](21 Department of Psychiatry)[ Department of Psychiatry](21 Department of Psychiatry), [Beitou Branch](Beitou Branch), [Tri-Service General Hospital](Tri-Service General Hospital), [School of Medicine](School of Medicine), [National Defense](National Defense)[ ](National Defense)Medical University, Taipei 114, Taiwan; [lcsyfw@gmail.com](lcsyfw@gmail.com)  \n22 D","cbCair8O50ryt1ii","https://ap.wps.com/l/cbCair8O50ryt1ii","pdf",1724532,21,"English","# Abstract\n## Therapeutic question and rationale\n## Methods: systematic review and network meta-analysis\n## Outcomes and statistical approach\n## Evidence certainty assessment","[{\"question\":\"What clinical uncertainty does the study address?\",\"answer\":\"It evaluates whether newer glucose-lowering therapies—DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors—modify the risk of incident gastric neoplasms.\"},{\"question\":\"What study design and evidence base were used?\",\"answer\":\"The work is a systematic review and network meta-analysis of randomized controlled trials in adults without baseline gastric neoplasms.\"},{\"question\":\"How were comparative risks estimated and checked?\",\"answer\":\"Frequentist random-effects network meta-analysis produced risk ratios with 95% confidence intervals, and Bayesian network meta-analysis was used as a sensitivity analysis.\"}]","Gastric Neoplasm Risk with DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT2 Inhibitors - Network Meta-Analysis of Randomized Trials | PDF",1790100591,53,[148,152,156],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/4805fbb70fe684e722c465406e5aafef.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/3764d87052956041d9f08a534641902d.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/ad655517e7fa5e0e302c43457b2e04de.webp",981,1387]